Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drugs

• Publication date

  2014-06-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-014-0247-zPMID 24958336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY

  2014cited by this paper
• Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

  2014influential reference
• Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

  2014cited by this paper
• Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

  2014influential reference
• In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.

  2014cited by this paper
• Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

  2014cited by this paper
• Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

  2014influential reference
• Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV‐Uninfected female subjects

  2014cited by this paper
• Hepatitis C virus: Here comes all-oral treatment

  2014cited by this paper
• P1112 LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH SOFOSBUVIR IN THE FISSION, POSITRON, FUSION AND NEUTRINO PHASE 3 STUDIES

  2014cited by this paper
• P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY

  2014cited by this paper
• P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS

  2014cited by this paper
• P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL

  2014cited by this paper
• P1171 INTEGRATED SAFETY ANALYSIS OF SOFOSBUVIR-BASED HCV TREATMENT REGIMENS FROM PHASE 3 STUDIES

  2014cited by this paper
• Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial

  2014cited by this paper
• Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies

  2014influential reference
• O66 SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS

  2014influential reference
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

  2014cited by this paper
• IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.

  2014cited by this paper
• Chronic hepatitis C: future treatment

  2014cited by this paper
• Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

  2014cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

  2014cited by this paper
• Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

  2013cited by this paper
• sofosbuvir in Combination With Pegifn and Ribavirin for 12 Weeks Provides High Svr Rates in Hcv-infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the Lonestar-2 Study : lb-4

  2013cited by this paper
• EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver ⇑

  2013cited by this paper
• Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

  2013influential reference
• 1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY

  2013cited by this paper
• Current prospects for interferon‐free treatment of hepatitis C in 2012

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013influential reference
• Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

  2013influential reference
• New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C

  2013influential reference
• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

  2013influential reference
• svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

  2013cited by this paper
• Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

  2013influential reference
• Interferon-Free Hepatitis C Therapy

  2012cited by this paper
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009influential reference
• The natural history of recurrent hepatitis C and what influences this

  2008cited by this paper

• 1'- and 4'-Cyano Modified Adenosine Analogs Against Prototypic Flavivirus RNA-Dependent RNA Polymerases.

  2026cites this paper
• A fold switch regulates conformation of an alphavirus RNA-dependent RNA polymerase

  2026cites this paper
• Mechanism of Inhibition of the Active Triphosphate Form of 2′-α-Fluoro,2′-β-bromouridine against Yellow Fever Virus RNA-Dependent RNA Polymerase

  2025cites this paper
• A fold switch regulates conformation of an alphavirus virus RNA-dependent RNA polymerase

  2025cites this paper
• Kyasanur Forest Disease Virus: Epidemiological Insights, Pathogenesis, Therapeutic Strategies, and Advances in Vaccines and Diagnostics

  2025cites this paper
• 5′-Guanidino Xylofuranosyl Nucleosides as Novel Types of 5′-Functionalized Nucleosides with Biological Potential

  2025cites this paper
• Application of Biomaterials in the Development of Enteric-Coated Luminar Capsule Microneedles for Selective Delivery of Sofosbuvir to the Liver: A Promising Treatment for Hepatitis C.

  2025cites this paper
• Optimizing Care for Reproductive-Age Women with Hepatitis C Virus

  2025cites this paper
• Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals

  2024cites this paper
• Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2

  2024cites this paper
• Novel analogues of a nonnucleoside SARS-CoV-2 RdRp inhibitor as potential antivirotics

  2024cites this paper
• Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea

  2023cites this paper
• Cell-Dependent Activation of ProTide Prodrugs and Its Implications in Antiviral Studies.

  2023cites this paper
• Recent Advances in Molecular Mechanisms of Nucleoside Antivirals

  2023cites this paper
• The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in the Context of the COVID-19 Pandemic

  2023cites this paper
• Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients

  2023cites this paper
• Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study.

  2023cites this paper
• Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

  2023cites this paper
• Diastereo- and enantioselective synthesis of compounds with a trifluoromethyl- and fluoro-substituted carbon centre.

  2022cites this paper
• Pyrimidine Nucleosides Syntheses by Late-Stage Base Heterocyclization Reactions

  2022cites this paper
• Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

  2022cites this paper
• Research on Solubility Measurement, Solvent Effects, Preferential Solvation, and Model Correlation of Sofosbuvir Form A in Different Pure and Binary Solvents

  2022cites this paper
• Potential drug development and therapeutic approaches for clinical intervention in COVID-19

  2021influential citation
• In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

  2021cites this paper
• Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral therapy

  2021cites this paper
• An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.

  2021cites this paper
• Fluorinated Rings: Conformation and Application.

  2021cites this paper
• Analytical Method Development and Validation for the Simultaneous Estimation of Metformin Hydrochloride and Alogliptin by RP-HPLC in Bulk and Tablet Dosage Forms

  2021cites this paper
• 2’‐Derivatisation of 3’‐ C‐ Methyl Pyrimidine Nucleosides

  2021cites this paper
• Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

  2021cites this paper
• Phosphoryl prodrugs: characteristics to improve drug development

  2021cites this paper
• Concurrent Determination of Daclatasvir and Sofosbuvir in Pure Binary Mixture and Their Combined Film Coated Tablets by a Simple Stability Indicating RP-HPLC Method

  2021cites this paper
• Novel Antiviral Strategies Against Emerging Arbovirus Infections

  2021cites this paper
• A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

  2021cites this paper
• Author names and affiliations

  2021cites this paper
• Cu-catalyzed hydroxycyclopropanol ring-opening cyclization to tetrahydrofurans and tetrahydropyrans: short total syntheses of hyperiones

  2020cites this paper
• Hepatitis C Virus

  2020cites this paper
• Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China

  2020cites this paper
• The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

  2020cites this paper
• COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts

  2020cites this paper
• Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.

  2019cites this paper
• Method development and validation of Sofosbuvir and iedipasvirin by HPLC: A Review

  2019cites this paper
• Successes, failures, and future prospects of prodrugs and their clinical impact

  2019cites this paper
• Cardiac Disorder in Chronic Hepatitis C

  2019cites this paper
• Simultaneous estimation of ledipasvir and sofosbuvir in bulk and its dosage forms by stability indicating RP-HPLC method

  2019cites this paper
• DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND LEDIPASVIR IN TABLET DOSAGE FORM

  2018cites this paper
• The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)

  2018cites this paper
• Electrochemical Method for the Determination of Three New Anti-Hepatitis C Drugs: Application in Human Blood Serum

  2018cites this paper
• New reactions and processes for the efficient synthesis of a HCV NS5b prodrug

  2018cites this paper
• UV-Spectrophotometric and Stability Indicating RP-HPLC Methods for the Determination of the Hepatitis C Virus Inhibitor Sofosbuvir in Tablet Dosage Form

  2018cites this paper
• CARDIOVASCULAR EFFECTS OF ORAL ANTIVIRAL TREATMENT FOR NON-CARDIAC HCV PATIENTS

  2018cites this paper
• Nano-magnetite/ionic liquid crystal modifiers of carbon nanotubes composite electrode for ultrasensitive determination of a new anti-hepatitis C drug in human serum

  2018cites this paper
• Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

  2018cites this paper
• Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan

  2018cites this paper
• IL28B is An Irrelevant Prognostic Factor for HCV in the Era of Highly Effective DAAs

  2018cites this paper
• Sofosbuvir: A Potential Treatment for Ebola

  2018cites this paper
• Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C

  2018cites this paper
• Novel and facile spectrophotometric techniques for the determination of sofosbuvir and ledipasvir in their tablet dosage form

  2018cites this paper
• A New RP-HPLC Method for the Simultaneous Assay of SOFOSBUVIR and LEDIPASVIR in Combined Dosage Form

  2017cites this paper
• Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C

  2017cites this paper
• Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C.

  2017cites this paper
• Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection

  2017cites this paper
• Assay and Dissolution Methods Development and Validation for Simultaneous Determination of Sofosbuvir and Ledipasvir by RP-HPLC Method in Tablet Dosage Forms

  2017cites this paper
• Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

  2017cites this paper
• Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection

  2017cites this paper
• Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives

  2017cites this paper
• Limiting the access to direct-acting antivirals against HCV: an ethical dilemma

  2016cites this paper
• Computational study on the binding and unbinding mechanism of HCV NS5B with the inhibitor GS-461203 and substrate using conventional and steered molecular dynamics simulations

  2016cites this paper
• Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus.

  2016cites this paper
• Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy

  2016cites this paper
• Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes.

  2016cites this paper
• Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

  2016cites this paper
• Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies

  2016cites this paper
• Daclatasvir: A Review in Chronic Hepatitis C

  2016cites this paper
• Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir

  2016cites this paper
• Simeprevir: A Review of Its Use in Patients with Chronic Hepatitis C Virus Infection

  2015cites this paper
• Emerging options for treating hepatitis C infection.

  2015cites this paper
• Drug–drug interactions of telaprevir and boceprevir in HCV‐monoinfected and HIV/HCV‐coinfected patients can modify the adherence

  2015cites this paper
• Neue Arzneimittel 2014

  2015cites this paper
• Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy

  2015cites this paper
• Simeprevir and sofosbuvir for treatment of hepatitis C infection.

  2015cites this paper
• Investigating the modulation of viral translation by the Hepatitis C virus nonstructural protein 5A

  2015influential citation
• Hepatitis C virus: Virology, diagnosis and treatment.

  2015cites this paper
• Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS.

  2015cites this paper
• Synthetic approaches to the 2013 new drugs.

  2015cites this paper
• Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.

  2014cites this paper
• Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance.

  2014cites this paper
• Recent Advances on Nucleotide Analogs and Mimetics: Synthesis and Biological Properties

  2013cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper
• 1 (cid:48) - and 4 (cid:48) -Cyano Modified Adenosine Analogs Against Prototypic Flavivirus RNA-Dependent RNA Polymerases

  year unknowncites this paper